A few day ago, Schering-Plough ceo Fred Hassan appeared on CNBC's Mad Money, where he spoke with Jim Cramer, the hyperactive host, about the controversy surrounding Vytorin. In particular, Cramer asked questions about the famous Enhance trial, which found the cholesterol pill wasn't any better at reducing arterial plague in the carotid artery compared with Zocor, and even found a statistically insignificant buildup.
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments